{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:36:05Z","timestamp":1790710565694,"version":"4.1.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T00:00:00Z","timestamp":1309305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0021758","type":"journal-article","created":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T21:09:11Z","timestamp":1309381751000},"page":"e21758","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":70,"title":["Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease"],"prefix":"10.1371","volume":"6","author":[{"given":"Karen M.","family":"Ashe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Bangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A.","family":"Cabrera-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Bercury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Nietupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G. F.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M. F. G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane P.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald K.","family":"Scheule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,6,29]]},"reference":[{"key":"ref1","first-page":"3827","article-title":"The GM2 Gangliosidoses.","author":"RA Gravel","year":"2001"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2\u20135 years of treatment: a report from the Gaucher Registry.","volume":"113","author":"NJ Weinreb","year":"2002","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.","volume":"75","author":"WR Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10545-007-0577-z","article-title":"Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.","volume":"30","author":"EH Davies","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10545-007-0783-8","article-title":"No justification for very high-dose enzyme therapy for patients with type III Gaucher disease.","volume":"30","author":"A Zimran","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1517\/13543784.10.3.455","article-title":"Substrate reduction therapy for glycosphingolipid storage disorders.","volume":"10","author":"RH Lachmann","year":"2001","journal-title":"Expert Opinions Investig Drugs"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.","volume":"116","author":"E Lukina","year":"2010","journal-title":"Blood"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.","volume":"5","author":"J Marshall","year":"2010","journal-title":"PLoS ONE"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","article-title":"Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial.","volume":"99","author":"JE Wraith","year":"2010","journal-title":"Molec Gen Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1073\/pnas.0407785102","article-title":"Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions.","volume":"102","author":"T Yamashita","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"35","key":"ref11","doi-asserted-by":"crossref","first-page":"12459","DOI":"10.1073\/pnas.0500893102","article-title":"Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth.","volume":"102","author":"R Jennemann","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/gene.20167","article-title":"Conditional LoxP-flanked glucosylceramide synthase allele controlling glycosphingolipid synthesis.","volume":"43","author":"T Yamashita","year":"2005","journal-title":"Genesis (New York, NY : 2000)"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","article-title":"Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.","volume":"96","author":"M Jeyakumar","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1433","key":"ref14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1098\/rstb.2003.1279","article-title":"Substrate reduction therapy in mouse models of the glycosphingolipidoses.","volume":"358","author":"FM Platt","year":"2003","journal-title":"Philosophical transactions of the Royal Society of London Series B, Biological sciences,"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1194\/jlr.M400411-JLR200","article-title":"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice.","volume":"46","author":"JL Kasperzyk","year":"2005","journal-title":"J Lipid Res"},{"issue":"41","key":"ref16","doi-asserted-by":"crossref","first-page":"26522","DOI":"10.1074\/jbc.273.41.26522","article-title":"Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase.","volume":"273","author":"HS Overkleeft","year":"1998","journal-title":"J Biol Chem"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2337\/db06-1619","article-title":"Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity.","volume":"56","author":"JM Aerts","year":"2007","journal-title":"Diabetes"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.","volume":"11","author":"K Sango","year":"1995","journal-title":"Nature Gen"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-5751-6-8","article-title":"Peripheral nervous system manifestations in a Sandhoff disease mouse model: nerve conduction, myelin structure, lipid analysis.","volume":"6","author":"MA McNally","year":"2007","journal-title":"J Neg Results Biomed"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1172\/JCI5542","article-title":"A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder.","volume":"103","author":"Y Liu","year":"1999","journal-title":"J Clin Invest"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.nbd.2004.04.012","article-title":"Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.","volume":"16","author":"U Andersson","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V97.1.327","article-title":"Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.","volume":"97","author":"M Jeyakumar","year":"2001","journal-title":"Blood"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/jm901281m","article-title":"Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.","volume":"53","author":"T Wennekes","year":"2010","journal-title":"J Med Chem"},{"issue":"Pt 4","key":"ref24","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/brain\/awg089","article-title":"Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.","volume":"126","author":"M Jeyakumar","year":"2003","journal-title":"Brain"},{"issue":"20","key":"ref25","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.97.20.10954","article-title":"Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation.","volume":"97","author":"R Wada","year":"2000","journal-title":"PNAS USA"},{"issue":"22","key":"ref26","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1073\/pnas.0400625101","article-title":"Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice.","volume":"101","author":"YP Wu","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"ref27","first-page":"551","article-title":"Neuronal accumulation of \u03b1- and \u03b2-synucleins in the brain of a GM<sub>2<\/sub> gangliosidosis mouse model.","volume":"14","author":"K Suzuki","year":"2003","journal-title":"Clin Neurosci Neuropath"},{"issue":"9","key":"ref28","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1172\/JCI2127","article-title":"Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice.","volume":"101","author":"F Norflus","year":"1998","journal-title":"J Clin Invest"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ana.20242","article-title":"NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.","volume":"56","author":"M Jeyakumar","year":"2004","journal-title":"Ann Neurol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ymgme.2010.05.001","article-title":"Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.","volume":"100","author":"KM Ashe","year":"2010","journal-title":"Molec Gen Metab"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1586\/eem.09.8","article-title":"Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brain.","volume":"4","author":"R Lachmann","year":"2009","journal-title":"Expert Rev Endocrin Metab"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10545-010-9047-0","article-title":"Therapeutic approaches for neuronopathic lysosomal storage disorders.","volume":"33","author":"R Schiffmann","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher&apos;s disease type 3.","volume":"64","author":"R Schiffmann","year":"2008","journal-title":"Annals Neurol"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/GIM.0b013e3181a1b5c5","article-title":"Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment.","volume":"11","author":"BE Shapiro","year":"2009","journal-title":"Genetics in Medicine"},{"issue":"1\u20132","key":"ref35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2009.06.005","article-title":"Substrate reduction therapy in juvenile GM2 gangliosidosis.","volume":"98","author":"GH Maegawa","year":"2009","journal-title":"Molec Gen Metab"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-010-9186-3","article-title":"Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up.","volume":"33","author":"M Masciullo","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1172\/JCI29224","article-title":"Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility.","volume":"116","author":"Y Yildiz","year":"2006","journal-title":"J Clin Invest"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1074\/jbc.M610544200","article-title":"Identification of the non-lysosomal glucosylceramidase as \u03b2-glucosidase 2.","volume":"282","author":"RG Boot","year":"2007","journal-title":"J Biol Chem"},{"issue":"45","key":"ref39","doi-asserted-by":"crossref","first-page":"32655","DOI":"10.1074\/jbc.M702387200","article-title":"Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis.","volume":"282","author":"CM Walden","year":"2007","journal-title":"J Biol Chem"},{"issue":"32","key":"ref40","doi-asserted-by":"crossref","first-page":"29496","DOI":"10.1074\/jbc.M302964200","article-title":"Inhibition of calcium uptake via the sarco\/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.","volume":"278","author":"D Pelled","year":"2003","journal-title":"J Biol Chem"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10545-010-9075-9","article-title":"Pathophysiology of neuropathic lysosomal storage disorders.","volume":"33","author":"C Bellettato","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"26","key":"ref42","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1056\/NEJM199106273242601","article-title":"Recovery of motor function after spinal-cord injury\u2013a randomized, placebo-controlled trial with GM-1 ganglioside.","volume":"324","author":"FH Geisler","year":"1991","journal-title":"New Engl J Med"},{"issue":"13","key":"ref43","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1096\/fj.02-0149fje","article-title":"Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.","volume":"16","author":"J Bodennec","year":"2002","journal-title":"FASEB"},{"issue":"15","key":"ref44","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/hmg\/ddn126","article-title":"Sphingosine kinase 1\/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease.","volume":"17","author":"YP Wu","year":"2008","journal-title":"Hum Molec Gen"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/hmg\/11.11.1343","article-title":"Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling.","volume":"11","author":"R Myerowitz","year":"2002","journal-title":"Hum Molec Gen"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/hmg\/6.11.1879","article-title":"Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.","volume":"6","author":"JQ Huang","year":"1997","journal-title":"Hum Molec Gen"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.intimp.2004.04.008","article-title":"Inhibition of glycolopid bisynthesis by <italic>N<\/italic>-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.","volume":"4","author":"C Shen","year":"2004","journal-title":"Int Immunopharma"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"e4723","DOI":"10.1371\/journal.pone.0004723","article-title":"Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation.","volume":"4","author":"M Van Eijk","year":"2009","journal-title":"PLoS ONE"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated \u03b1-synuclein activates microglia: a process leading to disease progression in Parkinson&apos;s disease.","volume":"19","author":"W Zhang","year":"2005","journal-title":"FASEB J"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4049\/jimmunol.0903480","article-title":"\u03b1-Synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1.","volume":"185","author":"E-J Lee","year":"2010","journal-title":"J Immunol"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymeth.2005.01.009","article-title":"Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry.","volume":"36","author":"AH Merrill","year":"2005","journal-title":"Methods (San Diego, Calif)"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0021758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T14:35:55Z","timestamp":1560350155000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0021758"}},"subtitle":[],"editor":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,6,29]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,6,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0021758","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,29]]}}}